Table 2 The clinical characteristics of the patients with previous history of TB infection and no history of infection
From: Skin thickness affects the result of tuberculin skin test in systemic sclerosis
Clinical characteristics | No history of TB infection N = 151 | History of TB infection N = 17 | p-value |
|---|---|---|---|
Female (%) | 98 (64.9) | 9 (52.9) | 0.33 |
dcSSc subset (%) | 109 (72.2) | 12 (70.6) | 0.86 |
Age at onset (years); mean ± SD | 50.9 ± 10.5 | 50.6 ± 11.2 | 0.86 |
Age on study date (years); mean ± SD | 57.9 ± 10.0 | 58.5 ± 11.2 | 0.89 |
Duration of disease (years); mean ± SD | 6.9 ± 5.4 | 7.9 ± 6.4 | 0.53 |
Serology | |||
Anti-topoisomerase I antibody positive (%) | 77 of 92 (83.7) | 10 of 12 (83.3) | 0.94 |
Anti-centromere antibody positive (%) | 23 of 57 (40.4) | 2 of 8 (25.0) | 0.47 |
BMI ≤ 18.5 kg/m2 (%) | 35 (23.2) | 6 (35.3) | 0.28 |
Clinical characteristics of SSc | |||
Raynaud’s phenomenon (%) | 69 (45.7) | 9 (52.9) | 0.57 |
Digital ulcer (%) | 28 (18.5) | 4 (23.5) | 0.62 |
Telangiectasia (%) | 43 (28.5) | 9 (52.9) | 0.04* |
Calcinosis cutis (%) | 6 (4.0) | 1 (5.9) | 0.71 |
Salt and pepper skin (%) | 60 (39.7) | 5 (29.4) | 0.41 |
Edematous skin (%) | 8 (5.3) | 2 (11.8) | 0.29 |
Tendon friction rub (%) | 20 (13.3) | 2 (11.8) | 0.86 |
Hand deformity (%) | 65 (43.1) | 7 (41.2) | 0.88 |
Synovitis (%) | 13 (8.6) | 0 | 0.21 |
Muscle weakness (%) | 7 (4.6) | 0 | 0.36 |
Esophageal involvement (%) | 77 (60.0) | 11 (64.7) | 0.28 |
Stomach involvement (%) | 19 (12.6) | 4 (23.5) | 0.21 |
Intestinal involvement (%) | 13 (8.6) | 1 (5.9) | 0.70 |
Interstitial lung disease (%) | 77 (51.0) | 8 (47.1) | 0.76 |
Pulmonary arterial hypertension (%) | 15 (9.9) | 1 (5.9) | 0.59 |
Renal crisis (%) | 2 (1.3) | 0 | 0.63 |
mRSS > 20 (%) | 20 (13.3) | 2 (11.8) | 0.86 |
Treatment | |||
Prednisolone (%) | 84 (55.7) | 8 (47.1) | 0.77 |
Low dose (%) | 36 (23.8) | 3 (17.7) | |
Moderate dose (%) | 48 (31.8) | 5 (29.4) | |
High dose (%) | 0 | 0 | |
Immunosuppressant (%) | 45 (29.8) | 5 (29.4) | 0.96 |
Methotrexate (%) | 12 (7.9) | 2 (11.8) | |
Cyclophosphamide (%) | 24 (15.9) | 3 (17.7) | |
Mycophenolate mofetil (%) | 8 (5.3) | 0 | |
Azathioprine (%) | 1 (0.7) | 0 | |